This review demonstrates the bioactivity of purine-derived N-nucleoside antibiotics, highlighting genomic data's role in discovering new antimicrobial agents.
Background The rise of antibiotic resistance underscores the urgent need for new antimicrobial agents. Nucleoside antibiotics are a structurally diverse class with broad biological activities, among which purine-derived N -nucleoside antibiotics ( N -NAs) are of particular interest as their purine-linked frameworks enable diverse enzymatic modifications that yield compounds with distinct pharmacological profiles. Aim of the review This review summarizes the bioactivity and biosynthetic logic of representative purine-derived N -NAs, including pentostatin-type compounds, angustmycins, and deazapurine analogues, to provide insights into the genome-based discovery of related natural products. Key scientific concepts of the review By outlining conserved enzymes and genetic features within known BGCs, we illustrate how core enzyme probes can be used for genome-guided mining of putative clusters. This approach emphasizes both the opportunities and challenges in predicting novel N -NA producers from genomic data. Conclusion Understanding the biosynthesis and genetic organization of N -NAs not only sheds light on their structural diversity but also provides a framework for genome mining. Specific subclasses such as pentostatin-, angustmycin-, and deazapurine-type compounds exhibit Structure–Activity relationships that could guide the rational design and genome-based discovery of new nucleoside antibiotics.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: